Ondansetron - a promising adjunctive treatment for persistent schizophrenia
Jayashri Kulkarni, Natalie Thomas, Abdul-Rahman Hudaib, Emorfia Gavrilidis, Caroline Gurvich
JOURNAL OF PSYCHOPHARMACOLOGY | SAGE PUBLICATIONS LTD | Published : 2018
BACKGROUND: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. AIMS: This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for peo..View full abstract
Awarded by Stanley Medical Research Institute
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Stanley Medical Research Institute (grant number 09T-1333).